OMER EBITDA
$133.02MTTM · USD
Period ending:
OMER FY EBITDAUSD
$0.00-$170.49M
2005-12-312025-12-31
Source: Financial Modeling Prep (FMP). Annual fiscal periods; reported in USD. Dates are period ends; a fiscal year may differ from a calendar year.
OMER ebitda history
Earnings before interest, taxes, depreciation, and amortization. The available annual fiscal periods series contains 21 observations from Dec 31, 2005 to Dec 31, 2025.
| Period ending | EBITDA (USD) |
|---|---|
| -1,832,000 | |
| -157,004,000 | |
| -143,156,000 | |
| -158,375,000 | |
| -170,491,000 | |
| -168,022,000 | |
| -60,039,000 | |
| -122,472,000 | |
| -41,900,000 | |
| -58,626,000 | |
| -71,314,000 | |
| -69,877,000 | |
| -37,128,000 | |
| -36,395,000 | |
| -26,227,000 | |
| -27,244,000 | |
| -18,436,000 | |
| -24,091,000 | |
| -22,565,000 | |
| -22,454,000 | |
| -7,366,000 |
Compare ebitda
Other companies in Health Care. Each page shows its own reporting periods and currency.
- Guardant Health Inc (GH) ebitda
- Bridgebio Pharma Inc (BBIO) ebitda
- Brightspring Health Services Inc (BTSG) ebitda
- Madrigal Pharmaceuticals Inc (MDGL) ebitda
- Ensign Group Inc (ENSG) ebitda
- Glaukos Corp (GKOS) ebitda
- Vaxcyte Inc (PCVX) ebitda
- Krystal Biotech Inc (KRYS) ebitda
All OMER financial metrics · OMER stock overview · How to interpret financial metrics
